HC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220

Benzinga · 4d ago
HC Wainwright & Co. analyst Robert Burns maintains Inhibrx Biosciences (NASDAQ:INBX) with a Buy and lowers the price target from $245 to $220.